Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 10(63), 2019

DOI: 10.1128/aac.00564-19

Links

Tools

Export citation

Search in Google Scholar

Molecular Basis of Class A β-Lactamase Inhibition by Relebactam

Journal article published in 2019 by Catherine L. Tooke ORCID, Philip Hinchliffe ORCID, Pauline A. Lang ORCID, Adrian J. Mulholland ORCID, Jürgen Brem ORCID, Christopher J. Schofield ORCID, James Spencer ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) producers, especially strains carrying the widely disseminated class A enzymes, are required. Relebactam, a diazabicyclooctane (DBO) BLI, is in phase 3 clinical trials in combination with imipenem for the treatment of infections by multidrug-resistant Enterobacteriaceae .